ProQR Therapeutics (NASDAQ:PRQR) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research report report published on Thursday morning.

A number of other equities research analysts have also recently commented on PRQR. HC Wainwright increased their target price on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $7.13.

ProQR Therapeutics Stock Up 6.7 %

Shares of NASDAQ PRQR opened at $3.67 on Thursday. The firm has a 50-day simple moving average of $3.04 and a 200-day simple moving average of $2.27. The stock has a market capitalization of $299.77 million, a price-to-earnings ratio of -11.47 and a beta of 0.26. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of PRQR. OneDigital Investment Advisors LLC increased its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. boosted its stake in ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after buying an additional 236,279 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).